Clinical Trials on Non-small Cell Lung Cancer (NSCLC) With Brain Metastases in Mexico

Total 303 results

Instituto Nacional de Cancerologia de Mexico

Recruiting

Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.

Non-small Cell Lung Cancer | Brain Metastases | EGFR Gene Mutation

Mexico
National Institute of Cancerología

Unknown

Gene-expression Profiles in CNS-metastatic Non-small Cell Lung Cancer

Lung Cancer | Metastasis | Brain Disease

Mexico
Instituto Nacional de Cancerologia de Mexico

Recruiting

Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC

Non-Small Cell Lung Cancer With EGFR Mutation

Mexico
AstraZeneca

Completed

A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients (KINDLE)

Non-small-cell Lung Cancer (NSCLC)

Mexico, Peru, Argentina, Taiwan, India, Thailand, Colombia, Uruguay, Chile, Dominican Republic
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy (HYPOGRYPHE)

Melanoma | Renal Cell Carcinoma | NSCLC | SCLC | Breast Carcinoma | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Brain Metastases, Adult

United States
Novartis Pharmaceuticals

No longer available

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Non-small Cell Lung Cancer (NSCLC)

United States, Argentina, Korea, Republic of, Hong Kong, Thailand, Mexico, Jordan, Colombia, India, Philippines
Instituto Nacional de Cancerologia de Mexico

Recruiting

Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations (METLUNG)

Non Small Cell Lung Cancer

Mexico
AstraZeneca

Approved for marketing

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Non Small Cell Lung Cancer (NSCLC)

Taiwan, Thailand, Turkey, Brazil, Philippines, Russian Federation, Romania, Austria, Hungary, Bulgaria, Latvia, India, Argentina, Australia, Estonia, Malaysia, Mexico, Singapore, South Africa
National Institute of Cancerología

Unknown

Concurrent Chemotherapy and Radiotherapy With Nitroglycerin in Patients With Locally Advanced Non-Small Cell Lung Cancer

Locally Advanced Non Small-Cell Lung Canger

Mexico
GlaxoSmithKline

Completed

Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer

Lung Cancer, Non-Small Cell

United States, Slovakia, Russian Federation, Hungary, Canada, Poland
National Institute of Cancerología

Unknown

Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker

Non Small Cell Lung Cancer

Mexico
CytRx

Terminated

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion

United States, Mexico, India, Ukraine, Bulgaria, Russian Federation
Merck KGaA, Darmstadt, Germany

Completed

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) (FLEX)

Non Small Cell Lung Cancer (NSCLC)

Sweden, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Turkey, United Kingdom, Germany, Poland, Ukraine, Argentina, Austria, Hungary, Netherlands, Slovakia, Taiwan, Chil... and more
Instituto Nacional de Cancerologia de Mexico

Recruiting

Alectinib Pharmacokinetic in Patients With NSCLC

ALK Gene Mutation | Non-small Cell Lung Cancer Stage IIIB

Mexico
Hoffmann-La Roche

Active, not recruiting

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)

Non-small Cell Lung Cancer (NSCLC)

United States, Belgium, Korea, Republic of, Canada, China, Denmark, Spain, Thailand, United Kingdom, Taiwan, Brazil, Germany, Mexico, Italy, Switzerland, Hong Kong, Japan, France, Turkey, New Zealand, Kenya, Poland
BeiGene

Recruiting

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NSCLC | Non-small Cell Lung Cancer

Japan, United States, France, Mexico, Germany, Argentina, Brazil, Korea, Republic of, Turkey
Instituto Nacional de Cancerologia de Mexico

Completed

Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK) (ALK)

Non Small-cell Lung Cancer

Mexico
Hoffmann-La Roche

Recruiting

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, China, Australia, Taiwan, Brazil, Japan, Argentina
AstraZeneca

Active, not recruiting

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)

Non-small Cell Lung Cancer NSCLC

United Kingdom, Belgium, United States, Korea, Republic of, Hungary, Japan, Russian Federation, Poland, Ukraine, India, Mexico, Netherlands
National Institute of Cancerología
Instituto Nacional de Enfermedades Respiratorias

Completed

Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

Mexico
AstraZeneca

Active, not recruiting

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)

Non Small Cell Lung Cancer NSCLC

Poland, United States, Taiwan, Thailand, Vietnam, Korea, Republic of, United Kingdom, Brazil, Hungary, Japan, Mexico, Peru, Russian Federation, China, Germany, South Africa, Ukraine, Bulgaria, Hong Kong
Bristol-Myers Squibb

Completed

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen (CheckMate153)

Non Small Cell Lung Cancer (NSCLC)

United States, Canada
Amgen

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC)

United States, Australia, Netherlands, Taiwan, Korea, Republic of, United Kingdom, Spain, Austria, Japan, Switzerland, Sweden, France, Czechia, Italy, Portugal, Hong Kong, Thailand, Singapore, Bulgaria, Turkey, Argentina, Belgium, G... and more
Instituto Nacional de Cancerologia de Mexico

Completed

Effect of Mirtazapine Versus Placebo in Patients With Non-small Cell Lung Cancer and Anorexia

Anorexia | Non-small Cell Lung Cancer

Mexico
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

Non-Small Cell Lung Cancer (NSCLC)

Russian Federation, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Sweden, Swit... and more
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

Non-small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, United Kingdom, Australia, Belgium, Brazil, Canada, China, Portugal, Spain, France, Germany, Poland, Hong Kong, Israel, Thailand, Turkey, Japan, Austria, Hungary, Italy, Taiwan, Netherlands, Greece, New... and more
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
University of Washington
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Malignant Pleural Effusion

United States
New Mexico Cancer Care Alliance
University of New Mexico Cancer Center; Lovelace Respiratory Research Institute

Terminated

Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
New Mexico Cancer Care Alliance
Novartis; Fred Hutchinson Cancer Center

Completed

Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer (6137p)

Non-small Cell Lung Cancer

United States
National Institute of Cancerología
Instituto Nacional de Enfermedades Respiratorias

Completed

K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications (007/055/OMI)

Non-Small Cell Lung Cancer

Mexico
Instituto Nacional de Cancerologia de Mexico

Completed

Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients

Phase II Clinical Trial | Ninety-six Histologically Confirmed NSCLC Patients With BM | Randomized 1:1 to Received TN Plus WBR or Only WBR | ICPFS Evaluated by Two Blinded and Independent Radio-oncologist With MRI

Mexico
Bio-Thera Solutions

Completed

A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer

Non-squamous Non-small Cell Lung Cancer

China, Mexico, South Africa, Turkey, Ukraine
Eli Lilly and Company

Completed

A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Mexico, Italy, Australia, Spain
Instituto Nacional de Cancerologia de Mexico

Unknown

Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients

Non-Small Cell Lung Cancer

Mexico
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Active, not recruiting

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Advanced or Metastatic NSCLC

United States, Spain, Taiwan, Japan, Italy
National Cancer Institute (NCI)

Terminated

Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery

Stage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma

United States
Instituto Nacional de Cancerologia de Mexico

Completed

Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | EGFR | HER-2

Mexico
Instituto Nacional de Cancerologia de Mexico

Completed

Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer

Lung Neoplasms | Small Cell Lung Carcinoma | Non-Small Cell Lung Cancer | Taste Disorders | Dysgeusia

Mexico
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

Philippines, Thailand, France, Korea, Republic of, Hong Kong, United States, Turkey, Malaysia, Taiwan, Brazil, Serbia, Greece, Slovakia, Peru, South Africa, Mexico, Vietnam, Bangladesh
Hoffmann-La Roche

Active, not recruiting

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of, United States, Canada, Belgium, France, Italy, Spain, Brazil, Australia, Germany, Turkey, Mexico
National Cancer Institute (NCI)

Completed

Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

United States, Mexico, Bolivia, Peru, Venezuela
AstraZeneca

Active, not recruiting

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE)

Non Small Cell Lung Carcinoma NSCLC

Denmark, United Kingdom, United States, Poland, Brazil, India, Japan, Mexico, Peru, Russian Federation, Turkey, China, Malaysia, Hong Kong, Korea, Republic of, Chile, Israel, Ukraine, Portugal, Greece, Bulgaria, Philippines, Sweden, A... and more
University of Maryland, Baltimore
Tragara Pharmaceuticals, Inc.

Completed

0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer

United States
Genentech, Inc.
Hoffmann-La Roche

Completed

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Non-Squamous Non-Small Cell Lung Cancer

Poland, Belgium, Spain, United States, Canada, South Africa, Russian Federation, Hong Kong, Taiwan, Japan, France, United Kingdom, Australia, Germany, Hungary, Korea, Republic of, Netherlands, Croatia, Serbia, Israel, Ukraine, Peru, Brazi... and more
Eli Lilly and Company

Completed

Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.

Non-Small-Cell Lung Carcinoma

Argentina, Brazil, Chile, Mexico
Bristol-Myers Squibb
Eli Lilly and Company; Clovis Oncology, Inc.; Exelixis

Withdrawn

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy (CheckMate 79X)

Carcinoma, Non-small Cell Lung Cancer

Netherlands, Norway, Belgium, Greece, United States, Argentina, Denmark, Mexico, Poland, Romania
Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

Australia, Russian Federation, United States, Argentina, Austria, Belgium, Brazil, Chile, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Romania, Spain, Switzerland, United Kingdom
Eli Lilly and Company

Completed

A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer

Non-small Cell Lung Cancer

Spain, France, United States, Taiwan, Canada, Netherlands, Mexico
AstraZeneca

Completed

Iressa Expanded Access Program (EAP)

Carcinoma | Neoplasm | Non-small-cell Lung | Metastases

United States

Clinical Trials on Non-small Cell Lung Cancer (NSCLC) With Brain Metastases in Mexico

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations